QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 recursion-pharmaceuticals-stock-surges-10-as-nvidia-powered-supercomputer-completion-sparks-investor-optimism

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) made waves Monday afternoon not only with the announcement of its groundbreaking...

Core News & Articles

 Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today anno...

 needham-reiterates-buy-on-recursion-pharmaceuticals-maintains-17-price-target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $17 price target.

 nvidia-backed-recursion-pharmaceuticals-stock-is-up-on-q1-earnings-everything-you-need-to-know

Recursion reported first-quarter revenue of $13.491 million, which beat analyst estimates of $12.65 million, according to Benzi...

 recursion-pharmaceuticals-q1-2024-gaap-eps-039-beats-042-estimate-sales-13491m-beat-12650m-estimate

Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimat...

 jim-cramer-says-this-energy-stock-is-terrific-calls-caseys-general-stores-a-winner

Cramer recommends selling PBR, buying EPD, LNG, RXRX, and CASY. Criticisms of AVGO's licensing changes dismissed. PBR and C...

 cathie-woods-ark-invest-sells-20m-coinbase-shares-as-bitcoin-trades-over-70k-buys-palantir-sells-nvidia-stock

On Thursday, Cathie Wood’s Ark Invest made significant trades involving Coinbase Global, Inc. (NASDAQ:COIN), Palantir Technolog...

 needham-reiterates-buy-on-recursion-pharmaceuticals-maintains-17-price-target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $17 price target.

 nvidias-ai-revolution-is-transforming-healthcare-with-johnson--johnson-and-ge-healthcare-partnerships

Nvidia announces partnerships with J&J and GE Healthcare to integrate generative AI into surgery and medical imaging at GTC...

 why-clover-health-investments-shares-are-trading-higher-by-11-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported b...

 nvidias-secret-weapon-is-not-just-chips-but-investing-15b-in-ais-rising-stars-report-unveils-ceo-jensen-huangs-10-year-vision

Additionally, the investments help Nvidia "build out the future ecosystem of businesses that depend on its technology" ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION